Modulation of Excitatory/Inhibitory Neurotransmission via Targeting GABAA-Gephyrin Signaling: Integrated In-Silico, In-Vitro, and In-Vivo Evidence in Parkinson’s Disease Models
Objective: To evaluate the neuroprotective potential of wogonin in modulating excitatory–inhibitory neurotransmission via GABAA receptor and gephyrin signaling in rat models of Parkinson’s disease (PD).…Polypharmacy and its Impact in Individuals with Parkinson’s Disease: Theory- and Data-Driven Approaches
Objective: The aim is to explore the relationship between high prescription drug use (polypharmacy), and its unintended effects on individuals with Parkinson’s Disease (PD). Background:…Icariin, a Flavonoid from Epimedium, Confers Dopaminergic Neuroprotection and Neuromodulation in MPTP-Induced Parkinsonian Rats
Objective: The present study aims to evaluate the neuroprotective and neuromodulatory properties of icariin in an MPTP-induced Parkinsonian rat model. Background: Parkinson Disease (PD) is…Ambulatory PEMF stimulation using the DCcure device improves rest and postural tremor in patients with PD
Objective: To evaluate the effects of ambulatory transcranial pulsed electromagnetic field (PEMF) stimulation on rest and postural tremor in patients with Parkinson’s disease (PD). Background:…Anti Tremorgenic Properties Of Eslicarbazepine Acetate in The Harmaline Induced Tremor Mouse Model
Objective: This study evaluated potential anti-tremor properties of eslicarbazepine acetate (ESL), an antiseizure medication approved for treatment of focal-onset epilepsy, in the harmaline-induced tremor mouse…Intestinal Levodopa Infusion Therapies in Advanced Parkinson’s Disease: A 6-Month Prospective Cohort Study
Objective: To evaluate 6-month changes in motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel (LCIG) or levodopa/entacapone/carbidopa intestinal…Interventions in Friedreich’s Ataxia and their Influence on Patient-centric Outcomes: A Systematic Review
Objective: The presented systematic review summarizes available pharmacological and non‑pharmacological interventions for patients with Friedreich's ataxia, their outcomes, and alignment with patient‑centered health domains as…Experiences of Patients with Parkinson’s Disease regarding Pharmacological Treatment in three Peruvian Regions
Objective: To explore the experiences of patients with Parkinson's disease (PD) regarding pharmacological treatment in three Peruvian regions with diverse geographic and cultural contexts. Background:…Clinical and Genetic Profile of the ACTIVATE Population: A Phase 2 Trial of BIA 28-6156 in GBA-PD
Objective: To characterize the patient population enrolled in the ACTIVATE study, a Phase 2 multicenter, randomized, double-blind, placebo-controlled trial assessing the efficacy, safety, tolerability, pharmacodynamics,…Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson’s Disease
Objective: To evaluate the long-term safety, tolerability, and PK of the oral, brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease. Background: Preclinical evidence…
- 1
- 2
- 3
- …
- 36
- Next Page »